Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC

Introduction. HCC is a challenge for clinical oncology. 1-year mortality for advanced HCC accounts for 66% in theRussian Federation. The results obtained in the combined Atezolizumab and Bevacizumab therapy in the advanced HCC cases are reported.Objective. To assess efficacy and safety of anti-VEGF/...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: I. А. Dzhanyan, М. V. Natrusova, V. V. Breder
Formato: Artigo
Idioma:Russo
Publicado em: Remedium Group LLC 2021-06-01
Colecção:Медицинский совет
Assuntos:
hcc
immunotherapy
atezolizumab
bevacizumab
anti-vegf/pd-l1
cirrhosis
Acesso em linha:https://www.med-sovet.pro/jour/article/view/6206
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados